vaccin
consid
one
signific
medic
intervent
infecti
diseas
hilleman
despit
success
major
obstacl
remain
develop
vaccin
pathogen
vaccin
exist
hepat
c
viru
hcv
emerg
pathogen
sever
acut
respiratori
syndrom
sar
improv
suboptim
vaccin
bacil
calmetteguerin
bcg
key
element
need
design
effect
vaccin
includ
identif
protect
antigen
robust
durabl
adapt
respons
must
gener
ii
compound
stimul
innat
immun
respons
hoeb
et
al
eg
bacteri
cell
wall
compon
iii
optim
deliveri
system
carri
dispens
antigen
immunostimulatori
cargo
appropri
cell
immun
system
key
gap
understand
area
signific
futur
gain
center
issu
relat
recent
develop
field
innat
immun
mechanist
underpin
adjuv
activ
use
novel
immun
potenti
vaccin
formul
upon
interact
pathogen
innat
immun
system
provid
first
line
defens
react
within
minut
minim
immedi
threat
pose
pathogen
addit
earli
activ
innat
immun
compon
serv
creat
inflammatori
environ
condit
host
effect
gener
adapt
immun
respons
iwasaki
medzhitov
rapid
activ
innat
immun
achiev
recognit
rel
conserv
molecul
found
associ
pathogen
essenc
innat
immun
system
evolv
detect
broad
conserv
structur
associ
infecti
agent
convers
adapt
immun
system
compris
antigenspecif
b
cell
focus
antigen
epitop
found
protein
carbohydr
cell
innat
immun
system
macrophag
dendrit
cell
nk
cell
neutrophil
rapidli
respond
microbi
pattern
pattern
recognit
receptor
first
line
defens
invad
pathogenstheir
earli
activ
also
provid
inflammatori
context
antigen
recognit
cell
adapt
immun
respons
despit
abil
respond
quickli
effect
innat
respons
limit
due
lack
fine
specif
although
slower
adapt
immun
respons
precis
incred
divers
antigen
receptor
surfac
tand
b
cell
memorytand
b
cell
activ
much
rapidli
compar
initi
primari
adapt
cell
respons
antigen
specif
focus
thu
memori
respons
goal
vaccin
provid
speed
specif
recognit
elimin
infecti
agent
deriv
pathogen
focus
respons
slower
due
time
need
expand
b
cell
clone
bear
antigen
receptor
appropri
specif
ultim
goal
natur
host
defens
prophylact
vaccin
gener
adapt
memori
respons
rapid
highli
focus
figur
target
innat
adapt
arm
immun
system
critic
achiev
goal
charl
jane
way
postul
immun
system
may
equip
trigger
innat
immun
respons
use
pattern
recognit
receptor
prr
engag
pathogenassoci
molecular
pattern
pamp
janeway
time
known
lipopolysaccharid
lp
lipotecho
acid
doublestrand
ds
rna
peptidoglycan
pathogen
compon
could
nonspecif
stimul
immun
cell
compon
function
vaccin
adjuv
ad
immun
regimen
along
specif
antigen
thu
addit
mircobi
compon
experiment
immun
lead
develop
robust
durabl
adapt
immun
respons
mechan
behind
potenti
immun
respons
well
understood
recent
prr
involv
innat
immun
respons
pamp
identifi
tabl
engag
prr
may
lead
activ
one
immun
cell
macrophag
neutrophil
dendrit
cell
dc
natur
killer
nk
cell
b
cell
prr
also
express
nonimmun
cell
epitheli
endotheli
cell
activ
cell
infect
possibl
vaccin
prrmediat
activ
cell
lead
secret
inflammatori
cytokin
chemokin
addit
may
lead
matur
migrat
key
antigenpres
cell
apc
dc
figur
postul
pamp
janeway
perhap
envis
highord
multimer
pattern
lattic
precis
spatial
arrang
immunostimulatori
compound
gave
rise
pathogen
recognit
subsequ
innat
immun
activ
howev
experiment
evid
suggest
prr
specif
primarili
driven
multimer
pattern
wellknown
pamp
specif
receptorligand
engag
appear
govern
recognit
pathogen
signatur
pattern
beutler
import
note
context
discoveri
novel
synthet
compound
could
stimul
prr
nevertheless
recent
shown
receptorligand
pair
cell
receptormajor
histocompat
complex
tcrmhc
interact
format
higher
order
structur
ligandreceptor
pair
may
necessari
transmit
potent
downstream
signal
janeway
postul
prr
confirm
year
later
drosophilla
transmembran
receptor
protein
toll
shown
regul
antifung
respons
lemaitr
et
al
soon
discoveri
medzhitov
clone
first
mammalian
tolllik
receptor
tlr
essenti
lp
recognit
medzhitov
et
al
base
sequenc
homolog
mani
mammalian
tlr
subsequ
clone
shown
respond
multitud
pathogen
ligand
tabl
prr
broadli
divid
two
class
one
lead
phagocytosi
scaveng
receptor
mannos
receptor
iglucan
receptor
gordon
other
nonphagocyt
tlr
nucleotid
bind
oligomer
domain
protein
nod
howev
tlrinduc
phagocytosi
may
due
indirect
effect
inflammatori
respons
report
doyl
et
al
name
suggest
phagocyt
receptor
upon
engag
ligand
lead
engulf
phagocyt
cell
macrophag
contrast
nonphagocyt
receptor
upon
engag
respect
ligand
lead
elabor
signal
transduct
cascad
distinct
cellular
activ
event
prr
shown
bind
ugand
directli
sato
et
al
lien
et
al
rutz
et
al
remain
seen
whether
gener
rule
whether
intermedi
protein
compon
involv
one
key
question
biolog
prr
justifi
larg
number
often
structur
differ
ligand
recogn
limit
number
receptor
one
way
explain
complex
ligand
recognit
implic
intermedi
protein
may
conserv
site
prr
bind
distinct
site
bind
differ
pamp
exampl
drosophilla
toll
shown
recogn
microbi
ligand
interact
spatzl
host
protein
directli
interact
microbi
compon
lemaitr
et
al
similarli
mammalian
recogn
lp
indirectli
lp
bind
protein
lbp
surfac
receptor
pmsss
activ
iimat
immun
cdi
rest
innat
immun
cell
b
cell
upon
stimul
tolllik
receptor
tlr
tissu
resid
dendrit
cell
bridg
innat
adapt
immun
undergo
matur
lead
increas
express
costimulatori
molecul
increas
surfac
express
mhcclass
ii
molecul
migrat
secondari
lymphoid
tissu
spleen
lymph
node
prime
antigenspecif
naiv
cell
take
place
secondari
lymphoid
organ
activ
cell
undergo
clonal
expans
provid
help
antigenspecif
b
cell
undergo
antibodi
class
switch
well
cd
cell
addit
activ
dendrit
cell
may
licens
cell
becom
cytotox
prrmediat
activ
b
cell
may
contribut
longterm
serolog
memori
bernasconi
et
al
schroder
et
al
moreov
shown
lbp
also
bind
structur
differ
peptidoglycan
moieti
pneumococc
cell
wall
pcw
mainli
signal
weber
et
al
find
suggest
addit
second
tier
pamp
recognit
intermedi
protein
lbp
creat
greater
divers
ligand
recognit
limit
set
receptor
like
tlr
famili
h
innat
immun
condit
host
subsequ
adapt
immun
goal
innat
immun
activ
twofold
limit
immedi
threat
direct
action
effector
cell
neutrophil
nk
cell
macrophag
etc
establish
microenviron
conduc
specif
adapt
immun
signal
tlr
well
nod
protein
result
mainli
activ
transcript
factor
nfkb
provid
inflammatori
context
rapid
activ
host
defens
akira
takeda
nfkb
pathway
control
express
proinflammatori
cytokin
tnfa
wherea
pathway
lead
product
antivir
type
interferon
ifnoc
ifnp
along
cytokin
variou
chemokin
monocyt
chemoattract
protein
mcp
macrophag
inflammatori
protein
mip
rant
releas
receptor
express
surfac
activ
cell
result
vascular
endotheli
cell
may
alter
surfac
express
selectin
intercellular
cell
adhes
molecul
icam
lead
extravas
select
retent
leukocyt
inflam
site
cellular
infiltr
consist
activ
monocyt
neutrophil
basophil
eosinophil
nk
cell
mani
also
express
tlr
subsequ
becom
activ
presenc
respect
ligand
secret
varieti
necessari
cytokin
chemokin
consequ
inflammatori
microenviron
monocyt
infiltr
site
differenti
macrophag
dc
latter
crucial
prime
naiv
helper
well
induc
cell
differenti
killer
cell
dc
subset
express
distinct
array
tlr
found
strateg
anatom
site
allow
respond
rapidli
microbi
invas
kadowaki
et
al
upon
captur
antigen
pampinduc
matur
dc
migrat
local
lymphoid
tissu
antigen
peptid
present
cell
via
mhc
class
class
ii
molecul
thu
start
clonal
expans
antigenspecif
cell
figur
besid
direct
effect
prime
specif
cell
innat
immun
respons
may
indirect
effect
suggest
dc
activ
tlr
may
gain
abil
inhibit
suppress
abil
regulatori
cell
treg
pasar
medzhitov
also
suggest
engag
b
cell
tlr
may
crucial
point
isotyp
switch
well
antibodi
secret
capabl
bernasconi
et
al
liu
et
al
henc
innat
immun
activ
crucial
robust
adapt
immun
inde
long
immunologist
dirti
littl
secret
establish
pampprr
recognit
concept
addit
nonspecif
microbi
compon
experiment
purifi
protein
immun
elicit
much
stronger
specif
respons
anderson
recent
grow
knowledg
variou
compon
mammalian
innat
immun
system
make
process
select
immun
potenti
compound
inform
thu
reduc
probabl
associ
toxic
increas
use
vaccin
formul
adjuv
histor
defin
function
vaccin
compon
enhanc
immunogen
antigen
vivo
adjuv
function
differenti
immunopotenti
deliveri
vehicl
immun
potenti
directli
activ
innat
immun
system
eg
induct
inflammatori
cytokin
wherea
deliveri
system
concentr
display
antigen
repetit
pattern
eg
cation
microparticl
target
antigen
apc
help
coloc
antigen
immun
potenti
ideal
immun
potenti
improv
effect
vaccin
acceler
gener
robust
immun
respons
ii
sustain
respons
longer
durat
iii
gener
antibodi
increas
avid
neutral
capac
iv
elicit
cytotox
lymphocyt
ctl
v
enhanc
immun
respons
individu
weaken
immun
system
eg
children
elderli
immunocompromis
adult
vi
increas
respond
nonrespond
ratio
given
vaccin
vii
reduc
amount
antigen
need
thu
reduc
cost
vaccin
program
earli
vaccin
research
mainli
emphas
better
humor
respons
result
current
licens
adjuv
aluminum
salt
gear
toward
enhanc
antibodi
respons
without
signific
elicit
thl
ctl
respons
lindblad
howev
need
effect
vaccin
may
prevent
chronic
viral
diseas
hiv
hcv
alter
paradigm
vaccin
toward
gener
cellular
respons
addit
neutral
antibodi
respons
moreov
detail
sophist
understand
biolog
individu
infecti
diseas
well
uniqu
characterist
protect
immun
respons
suggest
fewadjuvantsmanyvaccin
model
optim
solut
thu
batteri
specif
tailor
adjuv
candid
nextgener
vaccin
use
elicit
superior
quantit
qualit
memori
respons
need
explos
inform
innat
immun
gener
academ
research
laboratori
last
decad
slowli
use
gener
new
gener
immunopotenti
tackl
convent
well
emerg
infecti
diseas
end
mani
new
exist
adjuv
formul
test
variou
clinic
preclin
trial
tabl
tlr
largest
beststudi
famili
prr
type
integr
membran
glycoprotein
consider
cytoplasm
domain
homolog
receptor
structur
tlr
consist
extracellular
domain
contain
leucinerich
repeat
lrr
motif
lrr
domain
suggest
form
horseshoelik
concav
structur
thought
interact
ligand
either
directli
indirectli
intermedi
protein
intracellularli
conserv
amino
acid
cytoplasm
domain
known
tir
touill
receptor
domain
import
associ
adaptor
protein
thu
link
transmembran
receptor
downstream
signal
pathway
nod
protein
consist
three
main
region
lrr
domain
may
work
similar
lrr
domain
tlr
nuclear
oligomer
domain
essenti
nod
cluster
subsequ
signal
effector
motif
caspas
recruit
domain
lead
actual
signal
transduct
bind
signal
kinas
chamaillard
et
al
absenc
canon
oligomer
domain
known
whether
oligomer
tlr
take
place
whether
requir
signal
transmembran
protein
possibl
tlr
membran
aggreg
may
occur
transient
structur
lipid
raft
caveoli
tlr
famili
singl
abund
famili
protein
identifi
date
recogn
molecular
signatur
discov
mostli
base
homolog
search
ligand
receptor
either
identifi
express
receptor
cell
lack
human
embryon
kidney
hek
cell
use
mous
strain
express
particular
tlr
gene
target
natur
mutat
tlr
gene
share
consider
homolog
shown
qualit
differ
function
cooper
takeuchi
et
al
exampl
hela
cell
system
coexpress
result
increas
reactiv
neisseria
meningitid
compon
wylli
et
al
wherea
cooper
recogn
peptidoglycan
staphylococcu
aureu
ozinski
et
al
macrophag
respond
normal
tripalmitoyl
lipopeptid
bacteria
recogn
dipalmitoylderiv
lipopeptid
mycoplasm
origin
recognit
latter
restor
coexpress
function
cooper
may
due
physic
interact
individu
tlr
molecul
tap
tobia
interact
tlr
heterodim
one
describ
abil
collabor
innat
immun
receptor
may
also
help
gener
qualit
differ
microbi
compon
recognit
well
inflammatori
outcom
mukhopadhyay
et
al
observ
could
use
devis
assay
screen
novel
tlr
agonist
specif
block
monoclon
antibodi
well
transfect
hek
cell
demonstr
recognit
polyi
c
sequenc
dskna
sequenc
depend
matsumoto
et
al
addit
gene
target
mice
defect
respons
viral
rna
indic
involv
viral
rna
recognit
alexopoul
et
al
immunostain
analysi
monocytederiv
dc
well
transfect
b
cell
line
show
intracellular
local
respons
blockabl
monoclon
antibodi
thu
express
local
may
modul
either
matur
state
type
express
cell
matsumoto
et
al
lp
major
membran
compon
gramneg
bacteria
shown
crucial
sensor
lp
first
mammalian
tlr
clone
base
homolog
drosophilla
toll
medzhitov
et
al
histor
mous
strain
known
lp
hyporespons
subsequ
clone
mutat
cytoplasm
region
found
mice
explain
defect
signal
lp
hyporespons
poltorak
et
al
qureshi
et
al
although
establish
essenti
receptor
lp
respons
molecul
lbp
identifi
aid
lp
recognit
haziot
et
al
shimazu
et
al
akashi
et
al
moreov
also
implic
sensor
varieti
structur
diverg
pathogen
product
suggest
lp
recognit
one
mani
function
receptor
ohagan
valiant
cho
cell
express
found
respond
cultur
supernat
gramposit
gramneg
bacteria
purif
cultur
supernat
led
discoveri
bacteri
flagellin
stimulatori
compon
hayashi
et
al
sinc
flagellin
protein
varieti
bacteria
shown
agonist
life
cycl
infecti
agent
host
larg
extracellular
eg
mani
bacteria
intracellular
rapid
entri
cell
requir
surviv
continu
prolifer
eg
virus
bacteria
like
mycobacterium
leishmania
salmonella
thu
optim
recognit
ligand
viral
rna
bacteri
dna
requir
intracellular
receptor
wherea
bacteri
cell
wall
compon
lp
lipoprotein
best
detect
extracellularli
ligand
peptidoglycan
appear
recogn
extracellularli
well
intracellularli
whose
ligand
probabl
avail
extracellularli
surfac
express
nod
famili
protein
local
subcellular
organel
cytoplasm
therefor
focus
intracellular
pathogen
ligand
latter
group
sensor
also
may
requir
acid
compart
optim
recognit
natur
ligand
lee
et
al
base
sequenc
homolog
similar
ligand
purin
deriv
suggest
belong
common
subfamili
tlr
du
et
al
chuang
ulevitch
natur
ligand
bacteri
dna
moreov
speci
specif
observ
optim
ligand
recognit
thu
human
optim
recogn
cpg
oligonucleotid
sequenc
best
recogn
murin
vice
versa
bauer
et
al
observ
cellular
local
tlr
distinct
featur
prr
consid
experiment
screen
novel
immun
potenti
gene
target
mice
reveal
may
recogn
gurich
singlestrand
rna
lund
et
al
also
recogn
gurich
singlestrand
rna
function
human
inact
mice
probabl
due
amino
acid
delet
extracellular
domain
murin
isoform
jurk
et
al
loxoribin
low
molecular
weight
guanosin
analog
function
immun
potenti
recogn
human
heil
et
al
contrari
discrimin
ligand
recognit
resiquimod
stimul
human
well
hemmi
et
al
jurk
et
al
intracellular
regul
pathogeninduc
inflamm
includ
nod
famili
protein
nodi
shown
sens
peptidoglycan
motif
gramneg
bacteria
chamaillard
et
al
suggest
nodi
found
epitheli
cell
line
intestin
tract
thu
sensor
pathogen
gramneg
bacteria
gut
consider
homolog
nodi
specif
recogn
muramyl
dipeptid
girardin
et
al
express
cell
myeloid
lineag
well
muscos
epitheli
cell
gutierrez
et
al
thu
prr
express
extracellularli
well
intracellularli
depend
ligand
choic
sens
ugand
either
directli
indirectli
intermedi
protein
specif
signal
transduct
pathway
initi
lead
inflammatori
outcom
tlr
except
share
common
signal
pathway
util
adapt
protein
call
mydss
myeloid
differenti
factor
case
eg
shown
bind
directli
via
tir
domain
wherea
other
eg
anoth
intermedi
adaptor
molecul
known
tirap
tir
domaincontain
adaptor
protein
involv
ntermin
death
domain
bind
anoth
famili
signal
transduc
known
irak
receptorassoci
kinas
turn
bind
subsequ
activ
transcript
factor
nfkb
involv
yet
adaptor
protein
known
takl
figur
one
import
question
tlr
biolog
specif
signal
transduct
achiev
given
similar
cytoplasm
domain
multitud
adapt
protein
involv
tlr
signal
suggest
qualit
differ
signal
transduct
outcom
achiev
tlr
util
variou
combin
receptor
adapt
protein
comprehens
review
akira
et
al
contrast
tlr
signal
pathway
nod
protein
signal
pathway
associ
ligand
nodi
activ
nfkb
pathway
card
domain
format
signal
complex
receptorinteract
serinethreonin
kinas
rick
subsequ
activ
nfkb
mapk
pathway
lead
express
inflammatori
cytokin
chemokin
review
chamaillard
et
al
signal
prr
thu
involv
complex
rapidli
grow
set
transmembran
intracellular
adaptor
kinas
offer
wide
rang
potenti
target
vaccin
adjuv
given
plethora
natur
product
capabl
activ
innat
immun
mechan
research
develop
effort
exploit
immun
potenti
vaccin
adjuv
therapeut
aggress
although
vivo
proof
concept
establish
use
mani
natur
pamp
adjuv
therapeut
number
advanc
clinic
trial
trend
futur
suggest
increas
relianc
synthet
analog
due
mainli
lower
manufactur
regulatori
hurdl
associ
synthet
immun
potenti
highli
defin
standard
addit
synthet
platform
allow
ration
approach
optim
nextgener
compound
possess
greater
potenc
decreas
toxic
perspect
perhap
promis
immun
potenti
platform
recent
identifi
base
smallmolecul
approach
identif
imidizoquinolin
smallmolecul
immun
potenti
smip
indic
tradit
pharmaceuticalbas
druglik
molecul
exploit
vaccin
adjuv
immun
modul
hemmi
et
al
jurk
et
al
inde
imidizoquinolin
shown
enhanc
antigenspecif
respons
mous
model
therefor
potenti
develop
adjuv
human
vasilako
et
al
import
note
firstgener
imidizoquinolin
imiquimod
licens
antivir
well
anticanc
topic
therapi
vaccin
adjuv
indic
smip
offer
flexibl
platform
use
vaccin
adjuv
immun
therapi
smipbas
platform
hold
signific
potenti
design
develop
improv
vaccin
adjuv
numer
advantag
realiz
throughout
discoveri
develop
pipelin
smip
rather
natur
synthet
immun
potenti
chosen
platform
futur
discoveri
effort
incred
divers
scaffold
gener
combinatori
chemistri
abil
target
innat
immun
mechan
except
select
tri
test
drug
discoveri
engin
highthroughput
screen
ht
hit
lead
htl
optim
appli
immun
potenti
moreov
smallmolecul
platform
open
new
avenu
manipul
innat
immun
respons
provid
new
intracellular
target
signal
pathway
figur
later
develop
manufactur
smipbas
adjuv
provid
lowcost
highli
pure
standard
altern
exist
candid
immun
potenti
given
advantag
likelihood
divers
smip
famili
discov
appear
agonist
imidizaquinolin
repres
first
long
line
futur
smallmoleculebas
adjuv
therapeut
tradit
effort
devot
vaccin
research
toward
identifi
protect
antigen
rather
optim
adjuv
abl
chang
qualit
immun
respons
probabl
due
tempor
differ
peak
research
activ
adapt
innat
immun
latter
peak
recent
result
two
deliveri
system
aluminum
salt
lindblad
oilinwat
emuls
podda
direct
immun
potenti
approv
widespread
use
human
adjuv
prophylact
vaccin
lack
progress
approv
immun
potenti
adjuv
due
perceiv
toxic
risk
lack
comprehens
approach
toward
adjuv
discoveri
thu
increas
portfolio
immun
potenti
compound
use
new
subunit
vaccin
tailor
specif
requir
particular
vaccin
systemat
approach
toward
novel
adjuv
discoveri
need
rel
wellunderstood
outcom
engag
variou
prr
highthroughput
assay
develop
screen
larg
number
chemic
defin
compound
abl
trigger
ht
success
establish
drug
discoveri
research
search
inhibitor
variou
intracellular
protein
enzym
well
search
ligand
orphan
receptor
drug
discoveri
program
often
divers
chemic
librari
avail
screen
vitro
inhibit
target
predict
compound
vivo
activ
two
criteria
satisfi
ht
becom
tool
choic
screen
novel
immunopotenti
identif
small
druglik
chemic
imidazoquinolin
famili
ligand
suggest
ht
larg
divers
librari
small
molecul
appli
novel
adjuv
discoveri
gener
strategi
screen
outlin
figur
librari
divers
chemic
compound
natur
synthet
mine
immun
potenti
use
highthroughput
screen
ht
cellbas
assay
design
measur
gener
activ
innat
immun
cell
screen
target
toward
specif
receptor
signal
compon
innat
immun
system
astolllik
receptor
tlr
activ
compound
hit
identifi
primari
screen
confirm
priorit
base
level
potenc
select
hittolead
htl
optim
chemic
analog
initi
hit
gener
test
iter
fashion
identifi
compound
increas
potenc
solubl
secondari
screen
perform
evalu
mechan
action
toxic
paramet
htloptim
immun
potenti
lead
candid
formul
test
increas
compat
differ
deliveri
system
wvo
immunogen
toxic
studi
use
establish
vaccin
candid
conduct
identifi
lead
immun
potenti
put
develop
novel
vaccin
adjuv
compound
open
end
function
outcom
cytokin
secret
without
bia
toward
target
score
system
contrast
wellestabush
assay
tlr
engagementdriven
nfkb
activ
cytokin
secret
use
specif
identifi
compound
target
particular
pathway
regardless
approach
use
novel
compound
analog
identifi
ht
need
optim
develop
drug
discoveri
engin
appli
search
new
immun
potenti
htl
optim
iter
process
structur
modif
creat
analog
follow
screen
improv
activ
arriv
lead
optim
compound
lead
compound
thu
identifi
may
test
efficaci
experiment
vaccin
formul
use
establish
anim
model
benchmark
known
immun
potenti
quantiti
qualiti
immun
respons
judg
use
function
antibodi
cell
protect
infecti
challeng
observ
known
immun
potenti
capabl
induc
secret
inflammatori
cytokin
vitro
compound
also
act
effect
adjuv
vaccin
formul
use
basi
screen
compound
librari
famili
molecul
satisfi
criteria
methodolog
screen
straightforward
reli
establish
immunolog
assay
elisa
multiplex
cytokin
analysi
measur
cytokin
chemokin
produc
immun
cell
primari
cell
cell
line
random
screen
also
elimin
prior
assumpt
mode
action
thu
yield
compound
known
receptor
target
yet
identifi
unbias
screen
approach
compound
optim
thorough
investig
need
carri
ascertain
target
mode
action
done
use
avail
genom
proteom
approach
may
aid
identif
previous
unknown
target
immunolog
relev
recent
develop
understand
prrmediat
signal
pathway
subsequ
molecular
outcom
use
target
screen
thu
librari
natur
pathogen
product
peptid
sequenc
synthet
compound
screen
use
cell
express
specif
tlr
appropri
report
gene
identifi
agonist
compound
specif
cell
natur
express
tlr
hek
cell
cotransfect
nfkb
report
gene
tlr
cdna
novel
agonist
sought
outlin
tlr
ligand
welldefin
immunopotenti
subunit
vaccin
variou
tlr
ligand
cpg
ligand
imidazoquinolin
ligand
shown
stimul
vitro
cytokin
product
activ
nfkbdriven
report
gene
recent
peptid
altt
isol
bacteri
fimbria
shown
ligand
ogawa
uchida
also
anoth
peptid
isol
insect
abl
stimul
nk
cell
produc
ifni
chernysh
et
al
thu
immunomodul
also
base
peptid
combinatori
peptid
librari
consist
natur
modifi
amino
acid
screen
defin
tlrreadout
assay
strategi
explor
whether
link
peptid
immunostimul
frame
antigen
protein
provid
necessari
innat
immun
stimul
along
mount
adapt
respons
select
antigen
jackson
et
al
besid
select
agonist
prr
target
approach
identifi
inhibitor
known
immunolog
antagonist
neg
regul
tlr
signal
compound
potenti
posit
regul
immun
system
activ
nfkb
pathway
undertaken
intens
research
activ
lead
theoret
mechanist
understand
innat
immun
foundat
provid
systemat
approach
toward
immunopotenti
discoveri
envis
futur
vaccin
adjuv
research
increasingli
employ
tool
platform
modern
drug
discoveri
key
challeng
opportun
found
link
system
biolog
immun
system
grow
molecular
understand
adjuv
mechan
figur
ultim
goal
becom
predict
manipul
innat
immun
respons
molecular
level
give
rise
distinct
protect
respons
vaccine
achiev
goal
critic
gap
understand
innat
immun
potenti
need
fill
particular
import
identifi
structurefunct
relationship
innat
immun
agonist
molecular
target
identif
novel
structur
divers
immun
potenti
small
molecul
librari
could
provid
portfolio
vaccin
adjuv
candid
also
power
tool
mechanist
studi
innat
immun
activ
subunit
antigen
inher
possess
structur
stimul
innat
immun
system
often
shown
poor
immunogen
vaccin
import
difficult
diseas
target
hiv
hcv
herp
simplex
viru
hsv
neisseria
meningitid
either
clinic
trial
plan
stage
diseas
may
need
cellular
well
humor
respons
effect
resolut
also
diseas
tuberculosi
greater
understand
avail
qualiti
helper
respons
need
resolv
infect
recent
breakthrough
immunolog
infecti
diseas
also
allow
better
applic
improv
antigen
discoveri
formul
novel
immun
potenti
deliveri
system
thu
academ
institut
vaccin
industri
well
government
agenc
research
develop
effort
converg
toward
develop
nextgener
adjuv
sever
firstgener
candid
cpg
mpl
imidazoquinolin
shown
linkifig
mechan
system
folotogi
step
along
chain
becom
pieiiictiv
critic
gap
figur
link
molecular
mechan
system
biolog
adjuv
design
develop
longterm
goal
adjuv
immun
potenti
research
becom
increasingli
predict
ration
appreci
innat
immun
mechanist
underpin
adjuv
research
almost
exclus
empir
today
arm
new
tool
molecular
target
platform
abil
connect
molecular
mechan
toinvivo
outcom
possibleth
critic
gap
understand
right
lie
incomplet
knowledg
surround
targetligand
bind
howev
overal
gap
connect
level
interact
molecular
mechanismsign
transductioncellular
responsesimmun
networkssystem
biolog
need
fill
becom
truli
predict
see
color
plate
section
efficaci
experiment
anim
clinic
studi
human
cooper
et
al
mason
et
al
hengg
cusini
besid
use
vaccin
initi
sustain
robust
adapt
immun
respons
nextgener
immun
potenti
may
suitabl
use
acut
bioterror
threat
pathogen
organ
may
modifi
broad
antibiot
resist
evad
prophylact
vaccin
denni
case
rel
toxic
may
accept
face
probabl
mass
casualti
bioterror
weapon
government
agenc
direct
stake
explor
novel
immun
potenti
nation
secur
area
true
governmentalnoncivilian
invest
emerg
technolog
byproduct
nation
secur
research
usual
use
nongovernment
purpos
immun
potenti
platform
ideal
suit
dual
civiliangovernment
use
model
given
potenti
util
prophylact
vaccin
immunebas
therapi
bioweapon
countermeasur
although
heighten
accept
regulatori
agenc
well
commerci
vaccin
manufactur
improv
vaccin
adjuv
need
meet
challeng
futur
infecti
diseas
skeptic
due
new
technolog
carri
unknown
risk
still
unevalu
present
safeti
regulatori
hurdl
encount
addit
novel
immun
potenti
deliveri
system
final
vaccin
formul
may
signific
still
larg
ill
defin
key
focu
separ
potenti
increas
immun
toxic
improv
immunogen
adjuv
vaccin
current
understand
tradeoff
rudimentari
tool
model
develop
approach
question
ration
like
improv
formul
control
releas
potent
immun
potenti
limit
toxic
increas
efficaci
addit
grow
number
immun
potenti
target
divers
innat
immun
mechan
allow
identif
candid
improv
therapeut
indic
thu
select
optim
platform
develop
identifi
key
cellular
molecular
target
innat
immun
system
trigger
safest
effect
immun
respons
divers
pathogen
longterm
goal
earli
stage
hurdl
appear
high
publicpriv
partnership
fuel
research
develop
may
requir
overcom
partnership
alreadi
establish
area
hiv
biodefens
vaccin
research
like
govern
industri
cooper
particularli
difficult
vaccin
problem
lead
breakthrough
adjuv
develop
overal
despit
aforement
uncertainti
enter
dynam
period
vaccin
research
driven
larg
increas
understand
innat
immun
mechanist
understand
tool
manipul
system
grow
like
novel
immun
potenti
deliveri
system
make
signific
impact
vaccin
develop
near
futur
author
would
like
thank
nell
cronen
help
prepar
manuscript
